Iradimed (IRMD) Liabilities and Shareholders Equity (2013 - 2026)

Iradimed (IRMD) has 14 years of Liabilities and Shareholders Equity data on file, last reported at $114.4 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $114.4 million, up 12.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $444.3 million (up 15.64% YoY), and the FY2025 annual result was $108.8 million, up 10.63% from the prior year.
• Liabilities and Shareholders Equity advanced to $114.4 million in Q1 2026 per IRMD's latest filing, from $108.8 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $114.7 million in Q3 2025 and troughed at $72.4 million in Q1 2022.
• A 5-year average of $92.1 million and a median of $89.9 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity increased 0.19% in 2022, then gained 21.72% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $85.5 million in 2022, then increased by 7.77% to $92.2 million in 2023, then rose by 6.7% to $98.3 million in 2024, then gained by 10.63% to $108.8 million in 2025, then rose by 5.16% to $114.4 million in 2026.
• Business Quant data shows IRMD's Liabilities and Shareholders Equity at $114.4 million in Q1 2026, $108.8 million in Q4 2025, and $114.7 million in Q3 2025.